BridgeMD
New treatment option for Labor, Induced
Official title Use of Papaverine to Shorten the Second Stage/Duration of Labor in Pregnant Women After Cervical Ripening by Double-balloon Catheter
ClinicalTrials.gov ID: NCT07237880
What this study is testing
What is Papaverine 80 mg IV?
Papaverine 80 mg IV is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for labor, induced.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This prospective, randomized, double-blind controlled trial aims to evaluate whether intravenous papaverine, administered immediately after the removal of a double-balloon catheter used for cervical ripening, can shorten the duration of labor in term pregnant women undergoing induction of labor. Papaverine is an antispasmodic medication that relaxes smooth muscle and is commonly used in obstetrics, although its effect on labor progression following mechanical cervical ripening has not been fully studied.
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 50, women only. Healthy volunteers may be eligible.
You may be able to join if
- Pregnant individuals aged 18-50 years
- Singleton pregnancy
- Gestational age 37-42 weeks
- Admission for induction of labor with a double-balloon catheter
- Planned vaginal delivery
You likely can't join if
- Previous cesarean delivery
- Multiple gestation
- Contraindication to vaginal delivery
- Known hypersensitivity to papaverine
- Known major fetal anomaly
- Any condition requiring immediate delivery or precluding safe participation (as determined by the treating physician)
See the full eligibility criteria
- Pregnant individuals aged 18-50 years
- Singleton pregnancy
- Gestational age 37-42 weeks
- Admission for induction of labor with a double-balloon catheter
- Planned vaginal delivery
- Ability to provide informed consent
- Previous cesarean delivery
- Multiple gestation
- Contraindication to vaginal delivery
- Known hypersensitivity to papaverine
- Known major fetal anomaly
- Any condition requiring immediate delivery or precluding safe participation (as determined by the treating physician)
The study team makes the final eligibility decision.
Where it's taking place
- Hadera, Israel
Compensation & support
Compensation mentioned.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling female, 18 years to 50 years. Healthy volunteers may be eligible. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Hadera, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.